Seres Therapeutics Inc. (NASDAQ:MCRB)’s share price rose 6.4% during mid-day trading on Tuesday . The company traded as high as $32.78 and last traded at $32.47, with a volume of 248,489 shares traded. The stock had previously closed at $30.51.

MCRB has been the topic of a number of recent analyst reports. FBR & Co restated a “buy” rating on shares of Seres Therapeutics in a report on Friday. Cowen and Company restated a “buy” rating on shares of Seres Therapeutics in a report on Monday, June 13th. Canaccord Genuity restated a “buy” rating on shares of Seres Therapeutics in a report on Sunday, May 29th. Finally, Zacks Investment Research upgraded Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, April 21st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $43.86.

The firm’s 50-day moving average is $30.45 and its 200-day moving average is $28.11. The firm’s market cap is $1.28 billion.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings results on Monday, May 16th. The company reported ($0.50) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.48) by $0.02. The company earned $2.71 million during the quarter, compared to analyst estimates of $1.25 million. On average, equities analysts forecast that Seres Therapeutics Inc. will post ($1.81) earnings per share for the current fiscal year.

In related news, CEO Roger Pomerantz sold 74,049 shares of Seres Therapeutics stock in a transaction on Thursday, June 2nd. The stock was sold at an average price of $32.52, for a total transaction of $2,408,073.48. Following the sale, the chief executive officer now directly owns 257,741 shares in the company, valued at $8,381,737.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP David N. Cook sold 16,000 shares of Seres Therapeutics stock in a transaction on Wednesday, June 1st. The stock was sold at an average price of $29.43, for a total value of $470,880.00. Following the sale, the executive vice president now owns 144,673 shares in the company, valued at $4,257,726.39. The disclosure for this sale can be found here.

Other hedge funds have recently added to or reduced their stakes in the company. ProShare Advisors LLC purchased a new stake in Seres Therapeutics during the fourth quarter worth about $1,146,000. Morgan Stanley increased its stake in Seres Therapeutics by 225.3% in the fourth quarter. Morgan Stanley now owns 33,758 shares of the company’s stock worth $1,185,000 after buying an additional 23,381 shares in the last quarter. Finally, Jennison Associates LLC increased its stake in Seres Therapeutics by 1.9% in the fourth quarter. Jennison Associates LLC now owns 398,959 shares of the company’s stock worth $13,999,000 after buying an additional 7,259 shares in the last quarter.

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a range of biological drugs, Ecobiotic microbiome therapeutics. It is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome in the human body.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.